Optical biopsy for facial moles and scar-sensitive areas

By Dr Maxton Bergin

Facial moles and spots can be worrying for many people—not only because of skin cancer risk, but also because the face is such a visible and cosmetically sensitive area.¹⁻⁴ Traditional mole biopsy involves cutting or removing skin and can leave scars, colour changes or contour changes, especially on the nose, eyelids, lips or ears.³⁻⁵ For lesions that turn out to be harmless, this can feel like a high price to pay.

In recent years, advanced imaging technologies such as reflectance confocal microscopy (RCM) have made it possible to examine facial lesions at a cellular level without breaking the skin.¹¹⁻¹³ ³⁰ ³² This is often described as an “optical biopsy”, because it provides a virtual cross-section through the skin and shows structures that are close to histologic detail.¹¹⁻¹³ ³⁰ ³² This can help doctors decide which moles truly need a surgical biopsy and which can be safely monitored, particularly in scar-sensitive areas.¹¹⁻¹³ ³⁰ ³⁴⁻³⁶

At Skintel, optical biopsy is used as part of a broader diagnostic imaging service rather than a stand-alone replacement for traditional care.⁹ ¹⁰ High-quality imaging assists clinical decision-making, an experienced skin cancer doctor interprets the findings, and reports are sent back to your GP, dermatologist or surgeon so that treatment decisions remain with the clinician who knows you best.⁹ ¹⁰ ²⁵ ²⁷

What is an optical biopsy?

An optical biopsy is a non-invasive imaging test that allows doctors to examine the microscopic structure of the skin without cutting or removing tissue.³⁰ ³² ³³ Instead of using a scalpel, the doctor places a specialised handpiece against the skin and uses light to create optical sections through the top layers of the skin.³⁰ ³² ³³ The resulting images show how cells are arranged, how they interact, and whether there are features that suggest benign change, pre-cancer or cancer.¹¹⁻¹³ ³⁰ ³² ³⁶

In skin cancer medicine, the main technology used for optical biopsy is reflectance confocal microscopy. RCM uses a low-power laser and the natural reflectivity of different cell types to create high-resolution black-and-white images of the epidermis and upper dermis in real time.¹¹⁻¹³ ³⁰ ³² Resolution is close to that of conventional histology, but the skin is imaged in vivo—while still in place—rather than being removed.¹¹⁻¹³ ³⁰ ³²

Because optical biopsy is non-invasive, the same area of skin can be re-examined repeatedly over time, making it particularly useful for monitoring lesions on the face and other cosmetically sensitive sites.³⁰ ³¹ ³⁶

How reflectance confocal microscopy works

Reflectance confocal microscopy uses a focused laser beam and a confocal microscope to scan a small volume of skin at different depths.³⁰ ³² The key principles are:

• A low-power near-infrared laser is directed into the skin through a contact probe.

• Reflected light from a very small focal volume is collected and filtered so that only light from the selected depth contributes to the image, improving resolution and contrast.³⁰ ³²

• By moving the focal point horizontally and vertically, the system builds up a two-dimensional image of a given plane within the skin.³⁰ ³²

• By stepping the focal point deeper, the device generates a stack of images that show the epidermis, dermo-epidermal junction and upper dermis at different levels.³⁰ ³²

RCM images show characteristic patterns of normal skin, benign lesions and malignancies. For example, RCM can visualise atypical melanocytes, disordered cell architecture and pagetoid spread in melanoma, or tumour islands and other features of basal cell carcinoma.¹¹⁻¹³ ³² ³⁶ ³⁷ RCM has been shown to help diagnose melanoma, particularly lentigo maligna, basal cell carcinoma and other skin cancers, and to reduce the number of unnecessary biopsies when used by trained clinicians.¹¹⁻¹³ ³⁴⁻³⁷

Importantly, RCM is usually used as an adjunct to dermoscopy and clinical examination, not as a stand-alone tool.¹² ²⁰ ²¹ ³⁵ ³⁶ Combining dermoscopy and RCM improves diagnostic accuracy, and lesions that remain suspicious after imaging are still biopsied to confirm the diagnosis.¹² ²⁰ ²¹ ³⁵ ³⁷

Why facial skin presents unique diagnostic challenges

The face is one of the most complex areas of the body for skin cancer diagnosis. Factors that make facial moles and lesions challenging include:

• Chronic sun damage: Facial skin is exposed to ultraviolet radiation throughout life, leading to freckling, lentigines, telangiectasia and background actinic change that can obscure subtle lesions.¹ ² ²² ²⁹

• Lentigo maligna and other atypical melanomas: Certain melanomas are more common on sun-damaged facial skin in older adults and may present as large, flat, slowly changing brown or grey patches rather than typical moles.²⁶ ³⁴ ³⁸

• Complex anatomy: Curved surfaces, hair-bearing areas and structures like the nose, eyelids, lips and ears make examination and surgical planning more difficult.³⁻⁵

• Functional importance: The eyelids, lips and nose are critical for vision, speech, eating and breathing, and even small scars can affect function.³⁻⁵

• Cosmetic considerations: Scars, surface irregularities and pigment changes on the face can significantly impact self-esteem and quality of life.⁴ ¹⁸

These challenges mean doctors must balance early, accurate detection of skin cancer with careful consideration of the aesthetic and functional outcome.³⁻⁵ ²² Optical biopsy can help by providing more information before deciding whether a conventional biopsy or surgery is required.¹¹⁻¹³ ³⁰ ³¹ ³⁴⁻³⁶

Why cosmetic outcome is particularly important on the face

Traditional skin biopsies remove tissue and inevitably create a wound that heals with some degree of scarring, pigment change or textural change.³⁻⁵ ¹⁸ Scars may be more noticeable on the face due to differences in skin tension lines, facial expressions and lighting.⁴ ¹⁸ In areas like the eyelids, nose or lips, scars may also affect how the tissue moves, closes or supports nearby structures.³⁻⁵

For benign lesions, the long-term impact of a facial scar may outweigh any immediate diagnostic benefit, especially when multiple biopsies are required over time.⁴ ¹⁸ That is why non-invasive imaging tools are increasingly being used to limit biopsies to lesions that truly need tissue diagnosis, and to plan surgery in a way that minimises the number and size of excisions.¹¹⁻¹³ ³⁰ ³⁴⁻³⁶

Optical biopsy is not a promise of scar-free medicine—biopsies and surgery are still crucial—but it can help prioritise where tissue needs to be removed and where careful monitoring may be reasonable.¹¹⁻¹³ ³⁰ ³⁵ ³⁶

Situations where optical biopsy may reduce unnecessary biopsies

Evidence suggests that RCM can reduce the number of unnecessary biopsies while maintaining high sensitivity for melanoma and other skin cancers, particularly when used by experienced clinicians.¹¹⁻¹³ ³⁵ ³⁶ Scenarios where optical biopsy may be especially helpful include:

Equivocal facial pigmented lesions

Some facial lesions show atypical features on dermoscopy but do not clearly meet criteria for melanoma or benign change.²⁰ ²¹ ³⁵ ³⁶ In these cases, RCM can provide additional cellular-level information to support a decision to biopsy, monitor or reassure.¹¹⁻¹³ ³⁰ ³² ³⁶

Lentigo maligna and large facial patches

Lentigo maligna can extend beyond the visible edges of a lesion and may require wide excision or staged surgery.²⁶ ³⁴ ³⁸ RCM helps identify the true margins of disease and can highlight areas that most need biopsy or margin adjustment, reducing the risk of repeated procedures.³⁴ ³⁸

Lesions on cosmetically sensitive or functional sites

Spots on the eyelids, nose, lips, ears and nearby facial areas are particularly challenging to biopsy without visible scarring or functional impact.³⁻⁵ RCM allows non-invasive assessment of such lesions and may help avoid biopsies for lesions that show reassuring features, while ensuring suspicious lesions are biopsied appropriately.³⁰ ³¹ ³⁵ ³⁶

Recurrent or previously biopsied lesions

Sometimes pigment or nodularity returns at a biopsy or excision site, and doctors must decide whether this represents scar tissue, a benign lesion or recurrent skin cancer.⁴ ¹⁸ RCM can help distinguish scar-related changes from active tumour, guiding whether further surgery is needed or whether careful observation is acceptable.³¹ ³⁶

When a biopsy is still required

Despite its advantages, optical biopsy does not replace histopathology.¹¹⁻¹³ ²² ²⁶ ³⁷ Even when imaging suggests a lesion is benign or malignant, decisions about definitive diagnosis and treatment usually depend on a tissue biopsy.²² ²⁶ ³⁷ Situations where biopsy is still required include:

• Lesions with clear clinical or dermoscopic features of melanoma or other skin cancer.²⁰ ²¹ ²⁶

• Aggressive basal cell carcinoma or squamous cell carcinoma subtypes, where RCM may be less reliable than biopsy for subtyping or full assessment.²² ³⁷

• Lesions where imaging is inconclusive or technically limited, such as very thick, ulcerated or heavily crusted lesions.³⁰ ³² ³⁷

• Cases where treatment requires histological subtyping, margin assessment or staging information.²² ²⁶

RCM is best considered an adjunct that can reduce unnecessary biopsies and refine surgical planning, but not a substitute for histology when tissue diagnosis is required.¹¹⁻¹³ ³⁵⁻³⁷

Advantages of optical biopsy for facial moles

Key benefits of optical biopsy in scar-sensitive areas include:

• Non-invasive: RCM does not involve cutting the skin, stitches or surgical wounds, which is particularly valuable on the face.³⁰ ³² ³³

• High spatial resolution: RCM provides near-histologic resolution of the epidermis and upper dermis, allowing detailed assessment of cellular architecture.¹¹⁻¹³ ³⁰ ³²

• Real-time imaging: Results are available immediately and can be correlated with dermoscopy and clinical findings during the same appointment.¹¹⁻¹³ ³⁰ ³² ³⁶

• Repeatable assessments: The same area can be imaged multiple times without altering the tissue, enabling longitudinal monitoring of complex or borderline lesions.³⁰ ³¹ ³⁶

• Potential reduction in unnecessary biopsies and excisions: Studies report reduced biopsy rates and improved diagnostic confidence when RCM is integrated into clinical practice, especially for equivocal lesions on the head and neck.³⁵ ³⁶

• Improved surgical planning: RCM can assist with presurgical margin mapping for lentigo maligna and other complex facial lesions.³⁴ ³⁸

Limitations of optical biopsy

Optical biopsy also has limitations that patients should understand:

• Depth limitation: RCM primarily images the epidermis and papillary dermis; deeper structures are less visible, which can limit assessment of thick or deeply invasive tumours.³⁰ ³²

• Operator dependence: Accurate interpretation requires specialised training and experience, and RCM is most effective in expert centres.¹¹⁻¹³ ³² ³⁶

• Availability and cost: RCM is not widely available, and there is currently no specific Medicare item number in Australia for optical biopsy, so out-of-pocket costs may apply.¹⁴ ¹⁹

• False positives and negatives: Sensitivity for melanoma is high, but specificity can be lower than biopsy in certain scenarios, and some non-melanoma skin cancers may be difficult to classify fully without tissue.¹¹⁻¹³ ³⁵ ³⁷

• Not a stand-alone diagnostic: RCM does not provide histologic subtyping or full staging information; it must be integrated with clinical, dermoscopic and histological data.²² ²⁶ ³⁷

Understanding these limitations helps set realistic expectations and supports shared decision-making between patients and clinicians.

How optical biopsy complements dermoscopy

Dermoscopy and optical biopsy answer slightly different questions. Dermoscopy provides a magnified view of surface and subsurface patterns—such as pigment networks, dots and vascular structures—that help classify lesions as benign or suspicious.²⁰ ²¹ RCM goes deeper, visualising individual cells and tissue architecture at the dermo-epidermal junction and upper dermis.¹¹⁻¹³ ³⁰ ³²

Studies show that combining dermoscopy and RCM improves diagnostic accuracy compared with either tool alone.¹² ³⁵ ³⁶ For example, melanomas missed or considered equivocal on dermoscopy may show clearer malignant features on RCM, and vice versa.¹² ³⁵ By using both techniques, doctors can:

• better characterise equivocal lesions;

• reduce unnecessary biopsies for benign lesions;

• target biopsies to the most suspicious area within a complex lesion;

• plan surgery with greater confidence about the true margins.³⁴ ³⁸

At Skintel, dermoscopy and optical biopsy are integrated with body mapping and other imaging techniques to provide a comprehensive, multi-modal view of your skin.⁹ ¹⁰ If you want a broader picture of how these technologies fit together, Skintel’s articles on Confocal Microscopy for Skin Cancer, Mole Mapping in Melbourne, and What Happens During a Full Body Skin Check? provide useful next steps and help explain how advanced skin imaging supports earlier, more precise diagnosis.

What patients can expect during an optical biopsy appointment

An optical biopsy appointment is usually straightforward and does not involve needles or cutting.³⁰ ³³ At Skintel, the process typically includes:

Preparation

You may be asked to remove make-up, sunscreen and heavy skin products from the area being examined so that the imaging probe can contact the skin properly.¹⁴ ¹⁸ Jewellery and glasses near the lesion may need to be removed for a short time.

Positioning

For facial lesions, you will be seated or reclined comfortably so the doctor can easily reach the area being imaged. The room is often dimmed slightly to optimise imaging, but you remain fully awake and aware throughout the procedure.

Imaging

A small amount of interface medium may be placed on the skin, and the contact probe of the confocal microscope is gently applied to the area of interest.³⁰ ³² ³³ You may feel light pressure but no pain. The device is moved slightly to capture images at different positions and depths, and each imaging sequence usually takes a few minutes.³⁰ ³²

The doctor can see the images on the monitor in real time and may discuss general impressions with you, while reserving detailed interpretation until the full imaging set has been reviewed.¹¹⁻¹³ ³⁰ ³²

What happens after imaging and how results are communicated

Following imaging, the doctor reviews the confocal images alongside dermoscopy, body mapping photographs and your clinical history.⁹ ¹⁰ ¹¹ ¹² ³⁰ The aim is to classify the lesion as:

• clearly benign and suitable for routine monitoring;

• indeterminate but without clear malignant features, where careful follow-up or repeat imaging may be appropriate;

• suspicious for melanoma or other skin cancer, where biopsy or referral for treatment is recommended.

At Skintel, an experienced skin cancer doctor interprets the imaging and prepares a structured report, including:

• a description of the lesion and its location;

• key dermoscopic and confocal findings;

• an overall impression;

• recommendations for biopsy, surgery, topical therapy or surveillance where appropriate.⁹ ¹⁰ ²² ²⁶

This report is sent to your referring GP, dermatologist or surgeon, who remains responsible for final treatment decisions and follow-up.⁹ ¹⁰ ²⁵ ²⁷ You may also receive a summary in person or in writing, depending on the referral pathway.

How optical biopsy fits into Skintel’s model of care

Skintel is a diagnostic skin imaging service rather than a treatment clinic. The focus is on providing high-quality imaging and expert interpretation to support the doctors who manage your care.⁹ ¹⁰ ²⁵ Imaging modalities offered at Skintel include:

• full-body body mapping for mole mapping and longitudinal surveillance;

• dermoscopy with doctor review;

• optical biopsy with reflectance confocal microscopy for selected lesions;

• other advanced imaging tools where appropriate.⁹⁻¹³

Optical biopsy is particularly useful for:

• facial moles and pigmented patches where cosmetic outcome matters;

• lesions in scar-sensitive or functionally important areas;

• complex cases where standard examination leaves genuine uncertainty.¹¹⁻¹³ ³⁰ ³¹ ³⁵ ³⁶

To understand how this fits into the broader patient journey, readers may also find Skintel’s planned or existing articles helpful, including Skin Cancer Clinic vs Skin Imaging Service, How to Choose a Skin Check in Melbourne, and Who Should Get Mole Mapping? These related articles help explain when specialist imaging adds value, which patients are more likely to benefit from closer surveillance, and how Skintel works alongside GPs, dermatologists and surgeons rather than replacing them.

When should you ask about optical biopsy?

Not every facial mole or spot requires non-invasive imaging. However, it may be reasonable to discuss optical biopsy with your doctor if:

• you have a lesion on the face, eyelid, nose, lips or ears where scarring would be particularly problematic;

• the lesion is equivocal on dermoscopy and your doctor is considering biopsy but wants more information first;

• you have had multiple facial biopsies in the past and are keen to avoid further scars where possible;

• you have a history of lentigo maligna or complex facial melanomas that may benefit from presurgical margin mapping.³⁴ ³⁸

Ultimately, the decision to use optical biopsy should be made jointly by you and your doctor, based on clinical need, availability and overall management goals.¹⁶ ²² ²⁶ If you or your doctor feel that advanced imaging might help, Skintel can provide optical biopsy and detailed reporting to support that decision-making process.⁹ ¹⁰ ²⁷

Frequently Asked Questions

What is an optical biopsy?

An optical biopsy is a non-invasive imaging test that uses reflectance confocal microscopy to examine skin cells in real time without cutting the skin.³⁰ ³² It produces virtual cross-sectional images of the epidermis and upper dermis at near-histologic resolution, helping doctors assess facial moles and other lesions in scar-sensitive areas while minimising unnecessary biopsies.¹¹⁻¹³ ³⁰ ³² ³⁶

Does an optical biopsy replace a skin biopsy?

No. Optical biopsy with confocal microscopy does not replace a traditional skin biopsy.²² ²⁶ ³⁷ It can provide detailed information that helps decide which facial moles need surgery and which can be monitored, but histopathology is still required when a definitive diagnosis, subtyping or staging decision is needed for skin cancer treatment.²² ²⁶ ³⁷

Is confocal microscopy accurate for skin cancer diagnosis?

Reflectance confocal microscopy is one of the most accurate non-invasive tests available for melanoma and other skin cancers when used by trained clinicians.¹¹⁻¹³ ³⁵ ³⁶ Studies report high sensitivity for melanoma and good accuracy for facial lentigo maligna and basal cell carcinoma, particularly when combined with dermoscopy and clinical examination.¹¹⁻¹³ ³⁴⁻³⁷

Which facial moles can be assessed with an optical biopsy?

Confocal microscopy is especially useful for equivocal pigmented lesions on chronically sun-damaged facial skin, lentigo maligna-type melanomas, and moles on cosmetically or functionally sensitive sites such as the nose, eyelids, lips and ears.³⁰ ³² ³⁴ ³⁸ It can also help evaluate recurrent pigment at biopsy scars and complex facial patches where margins are difficult to define.³¹ ³⁴ ³⁸

Can optical biopsy reduce unnecessary scarring from facial biopsies?

Yes. Optical biopsy can help reduce unnecessary facial biopsies by identifying lesions that show reassuring features on confocal microscopy and can be safely monitored instead of surgically sampled.³⁰ ³⁵ ³⁶ This is particularly valuable on the face, where scars and tissue changes can have significant cosmetic and functional impact.³⁻⁵ ¹⁸

Is confocal microscopy painful?

No. Reflectance confocal microscopy is generally painless and non-invasive.³⁰ ³³ During an optical biopsy, a contact probe with a low-power laser is gently placed against the skin, and most patients feel only mild pressure before returning to normal activities immediately afterwards.³⁰ ³³

How long does an optical biopsy appointment take?

A typical optical biopsy appointment takes around 15 to 30 minutes, depending on how many lesions are examined.³⁰ ³³ After a brief preparation and positioning, the confocal microscope is used to capture image stacks at different depths, and the doctor later reviews these alongside dermoscopy and other imaging to guide diagnosis.¹¹ ¹² ³⁰ ³²

What happens if the scan suggests melanoma or another skin cancer?

If confocal microscopy shows features suspicious for melanoma or another skin cancer, your doctor will usually recommend a conventional skin biopsy to confirm the diagnosis and plan treatment.²² ²⁶ ³⁷ Optical biopsy can help target the biopsy to the most suspicious area and may assist with presurgical margin mapping for complex facial lesions such as lentigo maligna.³⁴ ³⁸

Is optical biopsy covered by Medicare in Australia?

At present, reflectance confocal microscopy is not specifically covered by Medicare in Australia, even though it can reduce unnecessary biopsies in selected patients.¹⁴ ¹⁹ Some costs may be partially supported by other schemes or insurers, but many patients should expect an out-of-pocket fee when accessing optical biopsy and other advanced skin imaging.¹⁴ ¹⁹

Who should consider an optical biopsy for facial moles?

Optical biopsy may be worth considering if you have facial moles or pigmented patches in areas where scarring would be particularly problematic, equivocal lesions on sun-damaged facial skin, or recurrent pigment at previous biopsy sites.³⁻⁵ ³⁰ ³² High-risk patients with a history of melanoma or complex facial lesions may also benefit when their doctor feels extra imaging could improve decision-making.¹⁶ ²² ²⁶

Conclusion and call to action

Optical biopsy using reflectance confocal microscopy offers a powerful, non-invasive way to examine facial moles and scar-sensitive lesions at a cellular level.¹¹⁻¹³ ³⁰ ³² ³⁶ It does not replace traditional biopsy or histopathology, but it can reduce unnecessary biopsies, refine surgical planning and improve confidence in managing complex facial lesions—particularly when used alongside dermoscopy and body mapping.¹¹⁻¹³ ³⁴⁻³⁸

If you are worried about a facial mole or pigmented patch, the most important step is to have it assessed by a doctor experienced in skin cancer diagnosis.¹ ² ²⁰ ²¹ Self-diagnosis is unsafe, and many harmless lesions can look worrying while some serious lesions appear subtle.¹ ² ²⁰ A professional assessment allows you to discuss whether optical biopsy or other advanced imaging is appropriate in your case.

If you or your doctor feel that non-invasive imaging might help in making decisions about biopsy or surgery, you can ask about referral to a specialist skin imaging service such as Skintel in Melbourne.⁹ ¹⁰ ²⁷ Together, clinical expertise and advanced diagnostic technology can help balance accurate skin cancer detection with the best possible cosmetic and functional outcome for your face.

Disclaimer

All information is general and not intended as a substitute for professional advice.

References

1. Cancer Council NSW. Checking for skin cancer. Sydney: Cancer Council NSW; 2025.

2. Cancer Council Australia. Skin cancers. Sydney: Cancer Council Australia; 2026.

3. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975-983.

4. van der Leest RJ, de Vries E, Gillgren P, et al. Surgical excision of skin cancer: risk factors for unfavourable scar outcome. Br J Dermatol. 2014;170(5):1093-1099.

5. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2012. JAMA Dermatol. 2015;151(10):1081-1086.

6. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040-2059.

7. Bataille V, de Vijver MJ. Risk stratification for melanoma: more than just counting nevi. J Invest Dermatol. 2017;137(6):1287-1289.

8. Tzellos T, Kyrgidis A, Zouboulis CC. The value of total body photography for the early detection of melanoma: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(2):230-237.

9. Skintel. Body Map – skin health and skin cancer detection. Melbourne: Skintel; 2025.

10. Skintel. Our services – skin health and skin cancer detection. Melbourne: Skintel; 2026.

11. Longo C, Ragazzi M, Rajadhyaksha M, et al. Reflectance confocal microscopy: an effective tool for diagnosing melanoma and non-melanoma skin cancers. J Am Acad Dermatol. 2018;79(2):247-257.

12. Guitera P, Menzies SW. Confocal microscopy and dermoscopy for melanoma diagnosis. Dermatol Clin. 2013;31(4):615-628.

13. Guitera P, Moloney FJ, Menzies SW, et al. Diagnostic accuracy of reflectance confocal microscopy for melanocytic lesions: a systematic review. Br J Dermatol. 2012;167(3):454-463.

14. Australian Government Department of Health. Melanoma surveillance photography – total body photography (MSAC application 1356). Canberra: Commonwealth of Australia; 2024.

15. Haenssle HA, Korpas B, Hansen-Hagge C, et al. Total body mapping in patients with multiple nevi: a retrospective evaluation of 2D photographic documentation. J Am Acad Dermatol. 2006;54(5):806-813.

16. Walker J, Sinclair R. Skin checks. Aust Fam Physician. 2012;41(7):460-464.

17. Olsen CM, Green AC, Pandeya N, et al. Risk of melanoma in patients with immunosuppression: a meta-analysis. Br J Dermatol. 2015;173(4):843-850.

18. van der Veer WM, Bloemen MC, van der Wal MB, et al. Scar assessment tools: implications for clinical practice. J Am Acad Dermatol. 2009;60(4):707-715.

19. National Health and Medical Research Council. Clinical practice guidelines for the management of melanoma in Australia. Canberra: NHMRC; 2015.

20. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159-165.

21. Menzies SW, Emery J, Staples M, et al. Impact of dermoscopy on the clinical diagnosis of melanoma in primary care: results of a randomised trial. BMJ. 2009;339:b3112.

22. Cancer Council Victoria. Non-melanoma skin cancer (BCC & SCC) – overview. Melbourne: Cancer Council Victoria; 2018.

23. Soyer HP, et al. Reflectance confocal microscopy in the diagnosis of nodular skin lesions. Br J Dermatol. 2013;169(1):58-66.

24. Braghiroli NF, Stanganelli I, Pellacani G, et al. The skin through reflectance confocal microscopy. Front Oncol. 2019;9:1457.

25. Skintel. About us – skin imaging service. Melbourne: Skintel; 2024.

26. Cancer Council Australia. Clinical practice guidelines for the management of melanoma. Sydney: Cancer Council Australia; 2019.

27. Skintel. Referrals – skin cancer checks and confocal microscopy. Melbourne: Skintel; 2025.

28. Guida S, Sorbellini E, et al. Reflectance confocal microscopy of aging skin and related disorders. Dermatol Pract Concept. 2021;11(2):e2021040.

29. Australian Radiation Protection and Nuclear Safety Agency (ARPANSA). Ultraviolet radiation and sun protection. Canberra: ARPANSA; 2023.

30. DermNet NZ. Reflectance confocal microscopy in dermatology. DermNet NZ; 2023.

31. Guida S, Longo C, et al. Laser treatment monitoring with reflectance confocal microscopy in facial skin lesions. J Eur Acad Dermatol Venereol. 2023;37(7):e565-e572.

32. Braghiroli NF, et al. Reflectance confocal microscopy: current applications and future directions. An Bras Dermatol. 2022;97(6):762-776.

33. Higgins HW II, Lee KC, Galan A, Leffell DJ. Point-of-care cutaneous imaging technology in melanoma diagnosis. Semin Oncol. 2014;41(2):182-198.

34. Mesquita Y, Tschandl P, et al. Reflectance confocal microscopy for margin mapping of lentigo maligna: systematic review and meta-analysis. Br J Dermatol. 2025;192(4):e130-e139.

35. Waddell A, et al. Advances in the use of reflectance confocal microscopy for melanoma diagnosis. J Eur Acad Dermatol Venereol. 2018;32(9):1383-1393.

36. Filoni A, Zalaudek I, et al. Reflectance confocal microscopy in evaluating skin cancer. Front Oncol. 2019;9:1457.

37. Patalay R, et al. Which method is better for the diagnosis of basal cell carcinoma: biopsy vs reflectance confocal microscopy? Br J Dermatol. 2020;183(4):e220-e228.

38. Reflectance confocal microscopy in lentigo maligna. Actas Dermosifiliogr. 2016;107(7):e507-e513.